Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Procedural Sedation Feasibility Study
NCT05783492Phase 3Withdrawn
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ketamine in Procedural sedation (PS). Primary endpoint: Adequacy of sedation at 1 hour. Planned start Jan 2024; status: withdrawn.
02
Drugs
ketamine
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT05783492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783492.